---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-043293"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:05:32.568128+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Indivior proposes redomiciliation to Delaware via new US parent IPI

## Summary
- Each Indivior PLC share exchanged for one share of new Delaware corporation Indivior Pharmaceuticals, Inc. (IPI).
- Timeline: shareholder circular mid-Nov 2025, EGM early Dec 2025, effective late Jan 2026.
- Scheme requires approval by 75% in value and majority in number of shareholders voting at EGM.
- No additional equity raised; IPI stock will trade on Nasdaq under symbol INDV.
- Proposed change aims to expand US capital markets presence and simplify governance.

## SEC filing metadata
- accession: 0001628280-25-043293
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000162828025043293/0001628280-25-043293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000162828025043293/indv-20251001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-043293
- JSON: https://secwatch.observer/filing/0001628280-25-043293.json
- Plain text: https://secwatch.observer/filing/0001628280-25-043293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.